Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy

References

• LachaineJYelleLKaizerLDufourAHopkinsSDeusonRChemotherapy-induced emesis: quality of life and economic impact in the context of current practice in CanadaSupp Cancer Therapy20052181187
   PubMedGoogle Scholar
• CohenLde MoorCAEisenbergPChemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settingsSupport Care Cancer200715549750317103197
   PubMed Web of Science ®Google Scholar
• HickokJTRoscoeJAMorrowGRKingDKAtkinsJNFitchJRNausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5- Hydroxytryptamine-3 antiemeticsCancer2003972880288612767103
   PubMed Web of Science ®Google Scholar
• GrunbergSMDeusonRMavrosPIncidence of chemotherapy-induced nausea and emesis after modern anti-emetics: perception versus realityCancer20041002261226815139073
   PubMed Web of Science ®Google Scholar
• GrunbergSMOsobaDHeskethPJEvaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an updateSupport Care Cancer200513808415599601
   PubMed Web of Science ®Google Scholar
• NavariRMProvincePSEmerging drugs for chemotherapy-induced emesisExpert Opin Emerging Drugs200611137151
   PubMedGoogle Scholar
• SimpsonKSpencerCMMcClellanKJTropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomitingDrugs2000591297131510882164
   PubMed Web of Science ®Google Scholar
• KimuraENiimiEWatanabeAStudy on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDPGan To Kagaku Ryoho1996234774818678501
   PubMedGoogle Scholar
• TaguchiTTsukamotoFWatanabeTUsefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancerGan To Kagaku Ryoho1999261163117010431583
   PubMedGoogle Scholar
• HeskethPJComparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomitingCancer Invest20001816317310705879
   PubMed Web of Science ®Google Scholar
• PerezEANavariRMKaplanHGEfficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesisSupport Care Cancer1997531379010987
   PubMed Web of Science ®Google Scholar
• HeskethPJNavariRMGroteTDouble blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancerJ Clin Oncol199614224222498708713
   PubMed Web of Science ®Google Scholar
• NavariRMGandaraDHeskethPComparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesisJ Clin Oncol199513124212397738628
   PubMed Web of Science ®Google Scholar
• NavariRMKoellerJMElectrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonistsAnn Pharmacother2003371276128612921512
   PubMed Web of Science ®Google Scholar
• RoilaFWarrDClark-SnowRDelayed emesis: moderately emetogenic chemotherapySupport Care Cancer20051310410815549426
   PubMed Web of Science ®Google Scholar
• LatreilleJPaterJJohnstonDUse of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapyJ Clin Oncol199816117411789508205
   PubMed Web of Science ®Google Scholar
• NavariRMMadajcwiczSAndersonNOral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placeboJ Clin Oncol199513240824167666101
   PubMed Web of Science ®Google Scholar
• The Italian Group for Antiemetic ResearchDexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapyN Engl J Med20003421554155910824073
   PubMed Web of Science ®Google Scholar
• GelingOEichlerHShould 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? systematic re-evaluation of clinical evidence and drug cost implicationsJ Clin Oncol2005231289129415718327
   PubMed Web of Science ®Google Scholar
• HickokJTRoscoeJAMorrowGR5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trialLancet Oncol2005676577216198982
   PubMed Web of Science ®Google Scholar
• NavariRMPathogenesis-based treatment of chemotherapy-induced nausea and vomiting: Two new agentsJ Support Oncol200318910315352652
   PubMedGoogle Scholar
• EisenbergPFigueroa-VadilloJZamoraRImproved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetronCancer2003982473248214635083
   PubMed Web of Science ®Google Scholar
• GrallaRLichinitserMVan Der VegtSPalonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronAnn Oncol2003141570157714504060
   PubMed Web of Science ®Google Scholar
• EisenbergPMacKintoshFRRitchPEfficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical studyAnn Oncol20041533033714760130
   PubMed Web of Science ®Google Scholar
• AaproMSGrunbergSMManikhasGMA phase III, double blind,randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAnn Oncol2006171441144916766588
   PubMed Web of Science ®Google Scholar
• SaitoMAogiKSekineIPalonosetron plus dexamethasone versus granisetron plus dexamethsone for prevention of nausea and vomting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trialLancet Oncol20091011512419135415
   PubMed Web of Science ®Google Scholar
• DeJongheBCHornCCChemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus)Am J Physiol Regul Integr Comp Physiol20092944R902R911
   Web of Science ®Google Scholar
• Aloxi (palonosetron HCl) injection prescribing information.MGI Pharma, IncBloomington, MN2003
   Google Scholar
• CantoreggiSParisiSVan LaarEPalonosetron, a new 5-HT3 antagonist does not alter antitumor efficacy of various chemotherapeutics in tumor bearing mice [abstract]Clin Cancer Res200396254S
   Web of Science ®Google Scholar
• DeckerGMDeMeyerESKiskoDLMeasuring the maintenance of daily life activities using the Fuctional Living Index-Emesis (FLIE) in patients receiving moderately emetogenic chemotherapyJ Support Oncol20064354116444851
   PubMedGoogle Scholar
• CartmellADFergusonSYanagiharaRProtection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT3 receptor antagonist [abstract]Proceedings of the American Society of Clinical Oncology2003 May 31–June 03Chicago
   Google Scholar
• YuZLiuWWangLThe efficacy and safety of palonosetron compared with Granisetron in preventing highly emetogenic chemotherapy-induced vomting in the Chinese cancer patients: a phaseII, multicenter, randimized, comparative clinical trialSupport Care Cancer2009179910218825421
   PubMed Web of Science ®Google Scholar
• GroteTHajdenbergJCartmellADPalonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy induced nausea and vomting after emetogenic chemotherapyJ Support Oncol2006440340817004515
   PubMedGoogle Scholar
• AaproMSMacciocchiAGridelliCPalonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patientsJ Support Oncol2005336937416218261
   PubMedGoogle Scholar
• HajdenbergJGroteTYeeLInfusion of palonosetron plus dexamethasone is effective and safe for the prevention of chemotherapy-induced nausea and vomitingJ Support Oncol2006446747117080735
   PubMedGoogle Scholar
• NavariRMEinhornLHLoehrerPJA phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomitingSupport Care Cancer2007151285129117375339
   PubMed Web of Science ®Google Scholar
• NavariRMEinhornLHLoehrerPJA phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomitingSupport Care Cancer20051352953415700131
   PubMed Web of Science ®Google Scholar
• EinhornLHBramesMJDreicerRPalonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancerSupport Care Cancer2007151293130017436025
   PubMed Web of Science ®Google Scholar
• NavariRMPrevention of emesis from multiple-day chemotherapy regimensJ Natl Compr Canc Netw20075515917239326
   PubMedGoogle Scholar
• MussoMScaloneRBonannoVPalonosetron and dexamethasone for the Prevention of acute and delayed nausea and vomiting in patients receiving multi-day ChemotherapySupport Care Cancer20091720520918839220
   PubMed Web of Science ®Google Scholar
• KovacALEberhartLKotarskiJA randomized double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour periodAnesth Analg200810743944418633021
   PubMed Web of Science ®Google Scholar
• CandiottiKAKovacALMelsonTIA randomized double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomtingAnesth Analg200810744545118633022
   PubMed Web of Science ®Google Scholar
• RojasCStathisMThomasAGPalonosetron exhibits unique molecular interactions with the 5HT3 receptorAnesth Analg200810735335518633005
   PubMed Web of Science ®Google Scholar
• ShahADeGrootTApseloffGPharmacokinetic evaluation and safety profile of a 15 minute versus 30 second infusion of palonosetron in healthy subjectsJ ClinPharmacol20064611391145
   Web of Science ®Google Scholar
• StoltzRCyongJShahAParisiSPharmacokinetic and safety evaluation of palonosetron, a 5HT3 receptor antagonist, in US and Japanese healthy subjectsJ Clin Pharmacol20044452053115102873
   PubMed Web of Science ®Google Scholar
• HajdenbergJSafety profile of palonosetron, a pharmacologically distinct 5-HT3 receptor antagonist recently approved for acute and delayed chemotherapy induced nausea [abstract]Blood2003102510b
   Web of Science ®Google Scholar
• MorganrothJParisiSMoresinoCHigh dose palonosetron does not alter parameters including QTC interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron versus moxifloxacin or placebo [abstract]European J Cancer Suppl200754158
   Web of Science ®Google Scholar
• BissoliFMcGiugganMBertazzoliMPost-marketing experience of palonosetron confirms a favorable benefit/risk profileSupport Care Cancer200513413A04
   Google Scholar
• KrisMGHeskethPJSomerfieldMRAmerican Society of Clinical Oncology. Guideline for Antiemetics in Oncology: UpdateJ Clin Oncol2006242932294716717289
   PubMed Web of Science ®Google Scholar
• ASCO.org [homepage on the internet]Alexandria, VAAmerican Society of Clinical Oncologyc2005–2009 [cited September 2009]. URL: http://www.asco.org/
   Google Scholar
• NCCN.org [homepage on the internet]Fort Washington, PAThe National Comprehensive Cancer Networkc2009 [cited September, 2009]. URL: http://www.nccn.org/
   Google Scholar
• MASCC.org [homepage on the internet]Metairie, LAMultinational Association of Supportive Care in Cancerc2009 [cited September, 2009]. Available from: http://www.mascc.org/.
   Google Scholar